- Home
- EFSH vs ZVSA Comparison
EFSH vs ZVSA Comparison
Compare EFSH & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSH
- ZVSA
- Stock Information
- Founded
- EFSH 1948
- ZVSA 2014
- Country
- EFSH United States
- ZVSA United States
- Employees
- EFSH N/A
- ZVSA N/A
- Industry
- EFSH Professional Services
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- EFSH Consumer Discretionary
- ZVSA Health Care
- Exchange
- EFSH Nasdaq
- ZVSA Nasdaq
- Market Cap
- EFSH 4.2M
- ZVSA 3.5M
- IPO Year
- EFSH N/A
- ZVSA N/A
- Fundamental
- Price
- EFSH $0.15
- ZVSA $1.22
- Analyst Decision
- EFSH
- ZVSA Strong Buy
- Analyst Count
- EFSH 0
- ZVSA 1
- Target Price
- EFSH N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- EFSH 2.7M
- ZVSA 69.7K
- Earning Date
- EFSH 04-16-2025
- ZVSA 03-24-2025
- Dividend Yield
- EFSH N/A
- ZVSA N/A
- EPS Growth
- EFSH N/A
- ZVSA N/A
- EPS
- EFSH N/A
- ZVSA N/A
- Revenue
- EFSH $69,415,140.00
- ZVSA N/A
- Revenue This Year
- EFSH N/A
- ZVSA N/A
- Revenue Next Year
- EFSH N/A
- ZVSA N/A
- P/E Ratio
- EFSH N/A
- ZVSA N/A
- Revenue Growth
- EFSH 228.22
- ZVSA N/A
- 52 Week Low
- EFSH $0.15
- ZVSA $0.98
- 52 Week High
- EFSH $717.62
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- EFSH 38.07
- ZVSA 44.26
- Support Level
- EFSH $0.15
- ZVSA $1.12
- Resistance Level
- EFSH $0.17
- ZVSA $1.29
- Average True Range (ATR)
- EFSH 0.02
- ZVSA 0.09
- MACD
- EFSH 0.04
- ZVSA -0.01
- Stochastic Oscillator
- EFSH 0.00
- ZVSA 37.04
About EFSH 1847 Holdings LLC
1847 Holdings LLC is a diversified holding company. It operates in Four segments: Retail and appliances, Retail and Eyewear, Construction, and Automotive Supplies. The company generates maximum revenue from the Construction segment. The firm, through its subsidiaries, provides a wide range of land application services and sells equipment and parts, primarily to the agricultural, construction, and lawn and garden industries.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.